latamen
ECB set to end negative policy rates soon

ECB set to end negative policy rates soon

09-06-2022 | Insight

In line with other major central banks, the ECB is pivoting its policy stance sharply towards tightening. A rate hike in July seems a certainty.

  • Martin van Vliet
    Martin
    van Vliet
    Strategist Global Macro Team

Speed read

  • An ECB rate hike in July looks to be a certainty
  • Unlike the Fed, the ECB is not yet pursuing quantitative tightening
  • We note the risk of the hiking cycle being paused or aborted by early 2023

Broadening and intensifying inflation pressures have prompted the ECB Governing Council to end net bond purchases under its asset purchase program (APP) as of 1 July. This paves the way for a 25 bps interest rate hike later next month, which will in all likelihood be followed by a further adjustment at the September meeting. Depending on the inflation outlook at the time, the size of the September move could well be 50 bps.

The ECB signaled that it foresees a “gradual but sustained” path of further rate hikes thereafter. As for the reinvestment of its quantitative easing (QE) holdings, the ECB decided to continue reinvesting the principal payments from maturing securities “until at least the end of 2024” (in the case of securities under the Pandemic Emergency Purchase Program (PEPP)) or “for an extended period of time past the date when it starts raising policy rates” (for securities under the APP). Importantly, this shows that, for now, the ECB is reluctant to follow central banks such as the US Fed on the path of quantitative tightening (QT).

President Christine Lagarde addressed concerns about a possible fragmentation in bond markets across the Eurozone at the ECB media conference. She once again gave the assurance that the ECB would deploy existing or “new” tools, if necessary, should there be a sharp and broad-based widening of government bond spreads over German Bunds. Her comments underline that some ECB governors are deeply worried about a possible revival of such fragmentation during the policy rate normalization process that lies ahead.

Market reaction thus far

By hinting at a series of rate hikes, which could include increments of more than 25 bps, the ECB gave a hawkish signal, which in turn drove bond yields higher. The 2-5-year segment of the curves led this move. Meanwhile, country spreads over Germany, especially that of Italy, widened, most likely because the ECB language on new tools to address bond market fragmentation disappointed in that it lacked substance on the development of such a tool.

Stay informed on our latest insights with monthly mail updates
Stay informed on our latest insights with monthly mail updates
Subscribe

Policy outlook

An ECB rate hike in July – the first in over ten years – now looks to be a certainty. An end to negative policy rates by September also seems to be a sure thing. Given the prospect that European inflation could rise to further above 8% over the coming months, we understand why financial markets are pricing in almost 150 bps of rate hikes over the four remaining ECB policy meetings this year. Notably, this encompasses two moves of 50 bps each, and two hikes of 25 bps each.

Looking beyond the next six months, though, we struggle to believe the ECB will be able to hike the depo rate by an additional 100 bps to around 2% and maintain that level, as is implied by forward rates (see chart). In fact, we doubt whether all Eurozone economies could structurally handle such a degree of tightening in financing conditions, especially given weakening cyclical growth. Nevertheless, we expect that a strong pricing out of rate hikes by the market will only occur when there are clear signs of an inflation retreat. Our view is that this could happen towards the end of this year or in early in 2023.

Source: Bloomberg, Robeco

As for the possibility of the ECB launching a new tool for addressing market fragmentation, there is in our view a decent chance that such a new policy instrument will be announced – and that conditions attached to it will be less strict than under the Outright Monetary Transactions (OMT) program. While we doubt it would prevent episodes of spread widening in European government bonds, the fact that it is available could cap any further widening of country spreads.

Subjects related to this article are:
Logo

Important information

The Robeco Capital Growth Funds have not been registered under the United States Investment Company Act of 1940, as amended, nor or the United States Securities Act of 1933, as amended. None of the shares may be offered or sold, directly or indirectly in the United States or to any U.S. Person (within the meaning of Regulation S promulgated under the Securities Act of 1933, as amended (the “Securities Act”)). Furthermore, Robeco Institutional Asset Management B.V. (Robeco) does not provide investment advisory services, or hold itself out as providing investment advisory services, in the United States or to any U.S. Person (within the meaning of Regulation S promulgated under the Securities Act).

This website is intended for use only by non-U.S. Persons outside of the United States (within the meaning of Regulation S promulgated under the Securities Act who are professional investors, or professional fiduciaries representing such non-U.S. Person investors. By clicking “I Agree” on our website disclaimer and accessing the information on this website, including any subdomain thereof, you are certifying and agreeing to the following: (i) you have read, understood and agree to this disclaimer, (ii) you have informed yourself of any applicable legal restrictions and represent that by accessing the information contained on this website, you are not in violation of, and will not be causing Robeco or any of its affiliated entities or issuers to violate, any applicable laws and, as a result, you are legally authorized to access such information on behalf of yourself and any underlying investment advisory client, (iii) you understand and acknowledge that certain information presented herein relates to securities that have not been registered under the Securities Act, and may be offered or sold only outside the United States and only to, or for the account or benefit of, non-U.S. Persons (within the meaning of Regulation S under the Securities Act), (iv) you are, or are a discretionary investment adviser representing, a non-U.S. Person (within the meaning of Regulation S under the Securities Act) located outside of the United States and (v) you are, or are a discretionary investment adviser representing, a professional non-retail investor. Access to this website has been limited so that it shall not constitute directed selling efforts (as defined in Regulation S under the Securities Act) in the United States and so that it shall not be deemed to constitute Robeco holding itself out generally to the public in the U.S. as an investment adviser. Nothing contained herein constitutes an offer to sell securities or solicitation of an offer to purchase any securities in any jurisdiction. We reserve the right to deny access to any visitor, including, but not limited to, those visitors with IP addresses residing in the United States.

This website has been carefully prepared by Robeco. The information contained in this publication is based upon sources of information believed to be reliable. Robeco is not answerable for the accuracy or completeness of the facts, opinions, expectations and results referred to therein. Whilst every care has been taken in the preparation of this website, we do not accept any responsibility for damage of any kind resulting from incorrect or incomplete information. This website is subject to change without notice. The value of the investments may fluctuate. Past performance is no guarantee of future results. If the currency in which the past performance is displayed differs from the currency of the country in which you reside, then you should be aware that due to exchange rate fluctuations the performance shown may increase or decrease if converted into your local currency. For investment professional use only. Not for use by the general public.

I Disagree